/C O R R E C T I O N -- Alteon Inc./

In the news release, Alteon (AMEX:ALT) Provides Corporate Update, issued earlier today by Alteon Inc. over PR Newswire, we are advised by the company that the first bullet point should be disregarded as it contained erroneous information. The complete, corrected first bullet follows:

  * Alteon plans to pursue development of lead compound alagebrium in high
    potential cardiovascular indications such as heart failure, after recent
    data presented at the American Heart Association (AHA) Scientific
    Sessions in November 2005 demonstrated continued positive results of
    alagebrium in patients with cardiovascular disease.  The AHA
    presentations included data from the Phase 2a PEDESTAL study in
    diastolic dysfunction in heart failure with impaired ejection fraction,
    as well as positive results from a Phase 2a study in endothelial
    function.  Alteon is in the process of preparing an IND specifically in
    heart failure in order to expand its clinical program in this
    therapeutic area.  Any continued development of alagebrium by the
    Company is contingent upon Alteon entering into strategic collaboration
    agreements for this product candidate which, among other things, would
    be required to include funding for product development.


PRNewswire -- Feb. 1

DATASOURCE: Alteon Inc.

Copyright